Loading...
Market
Will vortioxetine show positive results in human clinical trials for glioblastomas by September 30, 2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Published clinical trial results, ETH Zurich announcements, or reputable medical journals
Story
£40 Antidepressant Vortioxetine Found Effective Against Glioblastomas in ETH Zurich Study
Sep 20, 2024, 10:29 AM
Researchers have discovered that vortioxetine, a widely available antidepressant costing £40, shows unexpected effectiveness in treating glioblastomas, the most common and aggressive type of brain tumour. Studies conducted in cell cultures and mice by ETH Zurich and other research teams demonstrated that the drug can shrink tumours and kill tumour cells. This breakthrough suggests that vortioxetine could be repurposed to combat glioblastomas, offering a potentially new treatment avenue for this deadly brain cancer.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Complete Response (CR) • 25%
Partial Response (PR) • 25%
Stable Disease (SD) • 25%
Progressive Disease (PD) • 25%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worsening condition • 25%